Rebinyn (Coagulation factor IX [recombinant], glycoPEGylated) for Hemophilia

Overview Rebinyn is approved by the Food and Drug Administration (FDA) to treat bleeding episodes in adults and children with hemophilia B. Rebinyn can also be used for perioperative (before, during, and after surgery) care. The technical name of Rebinyn is Coagulation factor IX (recombinant), glycoPEGylated. Rebinyn is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia. How do I take it? Prescribing information states that Rebinyn is given as an intravenous injection. Rebinyn comes as a powder that must be reconstituted before injection. Side effects The FDA-approved label for Rebinyn lists common side effects including itching and injection site reactions. Rare but serious side effects listed for Rebinyn include thromboembolic events (dangerous blood clots), hypersensitivity reactions, and the development of inhibitors. For more details about this treatment, visit: Rebinyn - Novo Nordisk https://www.rebinyn.com/ Treatment of Hemophilia - Hemophilia Federation of America http://www.hemophiliafed.org/bleeding-disorders/hemophilia/treatment/